D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Similar documents
Package leaflet: Information for the user

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the user

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

1. What Panzyga is and what it is used for

CONSUMER MEDICINE INFORMATION LEAFLET

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

Package leaflet: Information for the user

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Package Leaflet: Information for the User

Package leaflet: Information for the user

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Before you are given Privigen

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. DaunoXome Injection 2mg/ml Concentrate for Solution for Infusion Daunorubicin

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

Privigen solution for infusion

Package leaflet: Information for the user

IMOJEV Japanese encephalitis vaccine (live, attenuated)

JvD/PL/ PACKAGE LEAFLET

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

1 What Engerix B is and what it is used for

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

(English translation of official Dutch version) PACKAGE LEAFLET JK/PL/

Package leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

1. What Faslodex is and what it is used for

CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)

GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

Package leaflet: Information for the patient

VAQTA Adult, Suspension for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

Package Leaflet: Information for the user

1 WHAT OCTAGAM 50 mg/ml IS AND WHAT IT IS USED FOR

SUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial

INTRATECT 100 g/l solution for infusion

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

1. What Miacalcic is and what it is used for

Package Leaflet: Information for the user. MAGNEVIST 2 mmol/l solution for injection dimeglumine gadopentetate

Package leaflet: Information for the user

HAVRIX 1440 and HAVRIX Junior

Package leaflet: Information for the patient

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

DATA SHEET RHESONATIV. NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection

SUMMARY OF PRODUCT CHARACTERISTICS

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron

PACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)

Package Leaflet: Information for the User Zofran tablets 4 mg and 8 mg ondansetron (as hydrochloride dihydrate)

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Package leaflet: Information for the user

Package leaflet: Information for the user. Poliomyelitis Vaccine (Inactivated) suspension for injection in pre-filled syringe

Eloxatin Oxaliplatin concentrated solution for injection

Package leaflet: Information for the user. Pharmalgen Bee Venom Pharmalgen Wasp Venom. 100μg/ml. powder and solvent for solution for injection

TYPHIM Vi, Solution for injection

IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin

HEALTHCARE SUPPLIES SPECIALISTS. Product information. amaproducts.com.au HEALTHCARE SUPPLIES SPECIALISTS

Package leaflet: Information for the user

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml Solution for Injection/Infusion Cisatracurium 5 mg/ml Solution for Injection/Infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

PACKAGE LEAFLET: INFORMATION FOR THE USER

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

Suspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular component) vaccine (adsorbed, reduced antigen content)

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Oxytocin APOTEX Solution for Injection Contains the active ingredient synthetic oxytocin

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

CONSUMER MEDICINE INFORMATION LEAFLET

RELISTOR. Methylnaltrexone bromide, Subcutaneous solution for injection. Consumer Medicine Information

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate

HERNOVIR 200 mg tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. Intratect 50 g/l solution for infusion. Human normal immunoglobulin (IVIg)

Package leaflet: Information for the user REPEVAX. Suspension for injection in pre-filled syringe

Package leaflet: Information for the user. Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion atosiban

Ventolin Injection 500 micrograms/ml salbutamol sulfate

Patient leaflet: Information for the user. Cytarabine 20mg/ml and 100mg/ml Solution for infusion or injection (Cytarabine)

PATIENT LEAFLET: INFORMATION FOR THE USER. SUBCUVIA 160 g/l Solution for Injection Human Normal Immunoglobulin

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

If you need the information on this leaflet in an alternative format, such as large text, or Braille please ring from the UK:

Transcription:

Package leaflet: Information for the patient D-Gam 50 micrograms/ml D-Gam 250 micrograms/ml Solution for injection human anti-d immunoglobulin Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, nurse or healthcare professional. - This medicine will be administered to you by your doctor, nurse or healthcare professional. - If you get any side effects, talk to your doctor, nurse or healthcare professional. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What D-Gam is and what it is used for 2. What you need to know before you are given D-Gam 3. How you are given D-Gam 4. Possible side effects 5. How to store D-Gam 6. Contents of the pack and other information 1. What D-Gam is and what it is used for D-Gam contains the active ingredient human anti-d immunoglobulin which protects against the effects of Rhesus D (Rh(D)) positive red cells in people who are Rhesus negative. It is made from blood plasma from screened donors. D-Gam is used during pregnancy if you are Rh(D) negative to prevent you from becoming sensitised to your baby s red cells if your baby is Rh(D) positive. D-Gam is also used if you are not pregnant but are Rh(D) negative and are receiving Rh(D) positive cells for any reason to prevent future complications. D-Gam is given if you are Rh(D) negative and your baby is Rh(D) positive: - as a routine preventative measure during pregnancy - soon after any accident or intervention during pregnancy which might lead to bleeding across the placenta - soon after an abortion when sensitisation is possible - soon after giving birth D-Gam can also be given if you are Rh(D) negative and have received blood components containing Rh(D) positive red blood cells to prevent future complications. Your doctor, nurse or healthcare professional will tell you if it is advisable for you to have D-Gam. 1

2. What you need to know before you are given D-Gam Do not use D-Gam: - if you are allergic (hypersensitive) to human anti-d immunoglobulin or any of the other ingredients of this medicine (listed in section 6) - if you are known to have antibodies to immunoglobulin A and have had an allergic reaction - if you are Rh(D) positive Warnings and precautions Talk to your doctor, nurse or healthcare professional before you are given D-Gam. - This medicine must not be injected into the vein, since it may cause a severe reaction if given in this way. Injections must be given to you by your doctor, nurse or healthcare professional into a muscle, usually the shoulder (deltoid). - For protecting Rh(D) negative women after delivery of a Rh(D) positive baby, this medicine is always given to the mother, not to the new-born baby. - True allergic reactions to this product are rare, when it is injected into the muscle as directed. Even if you have had this medicine before, you could still have a reaction, for example, low blood pressure and possible shock. In the case of shock, urgent medical advice is needed (see also section 4 Possible side effects ). - If you are lacking immunoglobulin A (IgA deficient) you might develop antibodies to IgA, although this is not common. If you know you already have antibodies to IgA, tell your doctor, nurse or healthcare professional before your injection. - If you suffer from high blood pressure, diabetes, a history of cardiovascular disease or a blood/blood related disorder, tell your doctor, nurse or healthcare professional before this medicine is injected. - If you are having this medicine because you have received Rh(D) positive red cells for whatever reason, you may be given larger doses than those used in pregnancy. Your doctor will assess you for the effects of very rapid break down of the injected red cells. - Immunoglobulins may increase the risk of having a blood clot, however this has not been seen with D-Gam. - If you develop pain, swelling and unusual warmth of a limb, sudden shortness of breath and chest pain worsening on deep breathing, numbness or weakness on one side, difficulty with speaking or confusion, contact your doctor or nurse immediately as these symptoms may indicate that you have a blood clot. - As some medicines may increase the risk of a blood clot, tell your doctor, pharmacist or nurse of all the medicines you are taking. - Tell your doctor, nurse or healthcare professional if you have any blood tests. This product will raise the level of various antibodies in your blood for several weeks. If you require a blood test during this period, tell your doctor, nurse or healthcare professional when you last had this product injected, as misleading positive results may occur with certain tests. - This medicine may not work very well in people who are overweight or very overweight. Talk to your doctor, nurse or healthcare professional for advice. - Large doses (over 5 ml) will be injected into different parts of the body. 2

Viral Safety When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include: careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded the testing of each donation and pools of plasma for signs of virus/infections the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections. The measures taken are considered effective for viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A (HAV) and parvovirus B19 viruses. Immunoglobulins have not been associated with HAV or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective. It is strongly recommended that every time you receive a dose of D-Gam the name and batch number of the medicine are recorded in order to maintain a record of the batches used. Other medicines and D-Gam Tell your doctor, nurse or healthcare professional if you are taking, have recently taken or might take any other medicines. Vaccinations Tell your doctor, nurse or healthcare professional of any vaccinations you have recently had or are about to have. Besides anti-d, D-Gam provides you with a range of antibodies. These antibodies will interfere with the response to some vaccines, especially MMR (measles, mumps and rubella) and varicella (chickenpox) vaccines. Such vaccinations should be given at least 3 weeks before D-Gam or not until 3 months after. D- Gam is unlikely to contain an antibody to yellow fever; so this vaccine can be given whenever needed. Pregnancy, breast-feeding and fertility D-Gam is intended for use in pregnancy and can be used during breast feeding. Immunoglobulins are excreted in human milk and may protect the baby from certain infections. Driving and using machines D-Gam has no influence on the ability to drive and use machines. 3

D-Gam contains sodium This medicinal product contains not more than 10 mg (0.5 mmol) sodium per 500 IU dose and per 1500 IU dose which are both essentially sodium-free. Talk to your doctor about this if you are on a low salt diet. 3. How you are given D-Gam This medicine will be given to you by your doctor, nurse or healthcare professional into a muscle, usually the shoulder (deltoid). Your doctor, nurse or healthcare professional will decide how much D-Gam you should receive. Injection should be as soon as possible after an accident or intervention during pregnancy and after delivery (ideally within 72 hours). No other medicines or fluids should be added to this product as their effects on the product have not been established. If you receive more D-Gam than you should If you are given more D-Gam than recommended, your doctor, nurse or healthcare professional may carry out some blood tests. It is not known what effects an overdose would have. If you have any further questions on the use of this medicine, ask your doctor, nurse or healthcare professional. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you feel unwell, tell your doctor immediately. Side effects may occur even if you have previously received human immunoglobulins and tolerated them well. On rare occasions, (may affect up to 1 in 1,000 people) you may experience a strong allergic reaction or you may experience a sudden drop in blood pressure. Tell your doctor or nurse immediately if you find it difficult to breathe, if you feel dizzy and faint or if you develop swellings and a red itchy rash. You may need additional treatment to correct your symptoms. Tell your doctor or nurse immediately if you feel ill with headaches, high temperature, neck stiffness, mental status changes, nausea and sickness, chills, generalised joint aches and pains or a rash during or within a few days after treatment. You may need additional treatment to correct your symptoms. Depending on your blood group, you may be more susceptible to your blood being damaged while you are being treated. If this happens your doctor or nurse may want to increase your blood level with blood transfusions. There may be some short-term discomfort at the site of injection such as swelling, warmth, pain, redness, itching or rash and hardening of the skin. The following side effects have been reported with human anti-d immunoglobulin. Not known: frequency cannot be estimated from the available data. 4

Tightening of throat or chest Wheezing Tongue swelling Swelling beneath lips and eyes Lightheaded, faint or feeling faint Hives (urticaria) Itching, redness of skin Rapid heart beat Chills Flushing Fever Headache Feeling sick or being sick Joint pain Back pain Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme: www.mhra.gov.co.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5. How to store D-Gam Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the containers after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 o C 8 o C). Do not freeze. Short periods (up to 1 week) of storage at room temperature (25 C), in the dark, will not damage the product. Do not use this medicine if you notice the solution is cloudy or has deposits. Your doctor, nurse or healthcare professional will dispose of any solution that remains, along with used syringes, needles and containers. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What D-Gam contains - The active substance is human anti-d immunoglobulin. - The other excipients are: sodium chloride, glycine and sodium acetate. What D-Gam looks like and contents of the pack 5

D-Gam is a clear or slightly yellow or pale brown solution in a clear glass container with a closure to prevent tampering. Pack sizes D-Gam 50 micrograms/ml solution for injection 1 x 500 IU vial D-Gam 250 micrograms/ml solution for injection 1 x 1500 IU vial Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Bio Products Laboratory Ltd., Elstree, WD6 3BX. United Kingdom For any information about this medicine, please contact the Marketing Authorisation Holder. Please e-mail: medinfo@bpl.co.uk This leaflet was last revised in March 2018 Version 9 6